-
公开(公告)号:US20190315862A1
公开(公告)日:2019-10-17
申请号:US16462754
申请日:2017-11-21
申请人: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE STRASBOURG , ETABLISSEMENT FRANÇAIS DU SANG (EFS)
发明人: Pierre MANGIN , Christian GACHET
IPC分类号: C07K16/28 , C12N15/115 , C07K14/705 , A61P35/04
摘要: The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of metastases. The inventors showed in vivo that lung metastasis in GPVI deficient mice are reduced compared to controls. They demonstrated that GPVI is involved in platetet interaction with tumor cells and this interaction is mediated by EMMPRIN.). Using an anti-EMMPRIN antibody, they showed that the adhesion of platelets to tumors cells is decreased. In particular, the present invention relates to a method for the prophylactic treatment of metastases in a patient suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent which inhibits the interaction between GPVI and EMMPRIN.
-
公开(公告)号:US20220135946A1
公开(公告)日:2022-05-05
申请号:US17547444
申请日:2021-12-10
申请人: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , Etablissement Français du Sang , Université de Strasbourg
IPC分类号: C12N5/078
摘要: The invention relates to a method of producing CD34+CD41dim megakaryocyte (MK) progenitor cells, and a substantially pure cell population of megakaryocyte precursor cells obtained by said method and compositions thereof. The invention also relates to a method of producing proplatelet-bearing MKs and/or platelets using the CD34+CD41dim cells.
-